Today: 19 April 2026
Western Digital stock ticks up as WDC sets Jan. 29 earnings, putting AI storage demand in focus

Western Digital stock ticks up as WDC sets Jan. 29 earnings, putting AI storage demand in focus

New York, January 13, 2026, 14:29 EST — Regular session

  • Shares of Western Digital climbed roughly 1.6% during afternoon trading
  • Company scheduled fiscal second-quarter results for Jan. 29, followed by a post-close call
  • Investors are gearing up for earnings that will put the AI-driven storage narrative to the test

Shares of Western Digital Corp climbed 1.6%, closing at $215.57 on Tuesday. The data-storage company said it will release its fiscal second-quarter results on Jan. 29, after markets close at 4 p.m. ET. During the session, shares fluctuated between $208.01 and $216.80.

That calendar update hits a stock already seeing rapid, sizable moves. Western Digital surged 5.8% in the previous session and has experienced several volatile swings since early January, reflecting ongoing attempts to gauge the cycle’s trajectory.

The surge in storage stocks is fueled by AI enthusiasm. Nvidia CEO Jensen Huang told analysts at CES that the memory storage sector is “a completely unserved market today.” His remarks sparked a rally last week in hard-drive and flash stocks, notably Western Digital and Seagate. markets.businessinsider.com

Zacks Equity Research reports that analysts are forecasting Western Digital to deliver earnings per share (EPS) of $1.92 for the current quarter. The consensus estimate for the full fiscal year stands at $7.66 per share, with quarterly revenue expected to hit roughly $2.91 billion.

Tuesday saw a split among peers. Seagate climbed roughly 1.5%, but Micron slipped around 2.3% by the afternoon session.

Western Digital makes hard drives for personal computers and cloud data centers. Right now, demand from hyperscalers—the largest cloud operators—is driving the stock’s near-term momentum.

The Jan. 29 report will offer investors a clearer view on whether pricing power remains intact and if customers continue favoring higher-capacity drives amid rising AI data demands. Guidance could prove just as crucial as the actual quarterly results.

This setup works both ways. Expectations have soared quickly, and any hint that orders are falling, supply is easing, or prices are softening could slam shares after their momentum-fueled run and talk of tight capacity.

Western Digital is up next, reporting after the bell on Jan. 29. The company’s conference call starts at 4:30 p.m. ET, where investors will be tuned in for any clues on demand and pricing that could either push the rally further or send it tumbling.

Stock Market Today

  • Brown-Forman (BF.B) Faces Valuation Debate After Strong Short-Term Rally
    April 18, 2026, 9:26 PM EDT. Brown-Forman's (BF.B) stock surged about 27% in one month, reversing last year's roughly 11% decline. The recent sharp rebound contrasts with a weaker long-term trend, highlighting momentum shifts. Despite shares trading near analyst price targets at $29.15, fair value estimates diverge widely. Simply Wall St's discounted cash flow (DCF) model values Brown-Forman at $37.78, suggesting undervaluation, while another model pegs fair value at $21.00, indicating the stock is roughly 39% overvalued. The gap reflects differing views on declining global alcohol consumption due to rising health awareness, which could pressure Brown-Forman's revenue growth. However, premium spirits and emerging market demand might offset some risks. Investors face critical decisions amid mixed signals, weighing whether current prices embed growth prospects or overestimate future earnings.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Chevron stock climbs as oil jumps, but drones and a Jan. 17 deadline keep CVX traders on edge
Previous Story

Chevron stock climbs as oil jumps, but drones and a Jan. 17 deadline keep CVX traders on edge

Alnylam stock dips as Amvuttra sales miss some forecasts; 2026 outlook in focus
Next Story

Alnylam stock dips as Amvuttra sales miss some forecasts; 2026 outlook in focus

Go toTop